Cargando…
A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.
Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients achieved a complete remission and 15 a partial re...
Autores principales: | Twelves, C. J., Dobbs, N. A., Curnow, A., Coleman, R. E., Stewart, A. L., Tyrrell, C. J., Canney, P., Rubens, R. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033534/ https://www.ncbi.nlm.nih.gov/pubmed/7947109 |
Ejemplares similares
-
Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.
por: Twelves, C. J., et al.
Publicado: (1994) -
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
por: Serin, D, et al.
Publicado: (2005) -
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
por: Iaffaioli, R. V., et al.
Publicado: (1995) -
Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
por: Dobbs, N. A., et al.
Publicado: (1998) -
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)